Global Amyloidosis Therapeutics Market Insights and Forecast to 2031

Report ID: 1564139 | Published Date: Sep 2024 | No. of Page: 111 | Base Year: 2023 | Rating: 4.9 | Webstory: Check our Web story
1 Study Coverage
    1.1 Amyloidosis Therapeutics Product Introduction
    1.2 Market by Type
        1.2.1 Global Amyloidosis Therapeutics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 AG-10
        1.2.3 ALN-ANG
        1.2.4 ALN-TTRsc02
        1.2.5 CAEL-101
        1.2.6 Canakinumab
        1.2.7 Others
    1.3 Market by Application
        1.3.1 Global Amyloidosis Therapeutics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 AL Amyloidosis
        1.3.3 AA Amyloidoses
        1.3.4 ATTR Amyloidoses
        1.3.5 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Amyloidosis Therapeutics Sales Estimates and Forecasts 2017-2028
    2.2 Global Amyloidosis Therapeutics Revenue Estimates and Forecasts 2017-2028
    2.3 Global Amyloidosis Therapeutics Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Amyloidosis Therapeutics Sales by Region
        2.4.1 Global Amyloidosis Therapeutics Sales by Region (2017-2022)
        2.4.2 Global Sales Amyloidosis Therapeutics by Region (2023-2028)
    2.5 Global Amyloidosis Therapeutics Revenue by Region
        2.5.1 Global Amyloidosis Therapeutics Revenue by Region (2017-2022)
        2.5.2 Global Amyloidosis Therapeutics Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Amyloidosis Therapeutics Sales by Manufacturers
        3.1.1 Global Top Amyloidosis Therapeutics Manufacturers by Sales (2017-2022)
        3.1.2 Global Amyloidosis Therapeutics Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Amyloidosis Therapeutics in 2021
    3.2 Global Amyloidosis Therapeutics Revenue by Manufacturers
        3.2.1 Global Amyloidosis Therapeutics Revenue by Manufacturers (2017-2022)
        3.2.2 Global Amyloidosis Therapeutics Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Amyloidosis Therapeutics Revenue in 2021
    3.3 Global Amyloidosis Therapeutics Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Amyloidosis Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Amyloidosis Therapeutics Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Amyloidosis Therapeutics Sales by Type
        4.1.1 Global Amyloidosis Therapeutics Historical Sales by Type (2017-2022)
        4.1.2 Global Amyloidosis Therapeutics Forecasted Sales by Type (2023-2028)
        4.1.3 Global Amyloidosis Therapeutics Sales Market Share by Type (2017-2028)
    4.2 Global Amyloidosis Therapeutics Revenue by Type
        4.2.1 Global Amyloidosis Therapeutics Historical Revenue by Type (2017-2022)
        4.2.2 Global Amyloidosis Therapeutics Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Amyloidosis Therapeutics Revenue Market Share by Type (2017-2028)
    4.3 Global Amyloidosis Therapeutics Price by Type
        4.3.1 Global Amyloidosis Therapeutics Price by Type (2017-2022)
        4.3.2 Global Amyloidosis Therapeutics Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Amyloidosis Therapeutics Sales by Application
        5.1.1 Global Amyloidosis Therapeutics Historical Sales by Application (2017-2022)
        5.1.2 Global Amyloidosis Therapeutics Forecasted Sales by Application (2023-2028)
        5.1.3 Global Amyloidosis Therapeutics Sales Market Share by Application (2017-2028)
    5.2 Global Amyloidosis Therapeutics Revenue by Application
        5.2.1 Global Amyloidosis Therapeutics Historical Revenue by Application (2017-2022)
        5.2.2 Global Amyloidosis Therapeutics Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Amyloidosis Therapeutics Revenue Market Share by Application (2017-2028)
    5.3 Global Amyloidosis Therapeutics Price by Application
        5.3.1 Global Amyloidosis Therapeutics Price by Application (2017-2022)
        5.3.2 Global Amyloidosis Therapeutics Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Amyloidosis Therapeutics Market Size by Type
        6.1.1 North America Amyloidosis Therapeutics Sales by Type (2017-2028)
        6.1.2 North America Amyloidosis Therapeutics Revenue by Type (2017-2028)
    6.2 North America Amyloidosis Therapeutics Market Size by Application
        6.2.1 North America Amyloidosis Therapeutics Sales by Application (2017-2028)
        6.2.2 North America Amyloidosis Therapeutics Revenue by Application (2017-2028)
    6.3 North America Amyloidosis Therapeutics Market Size by Country
        6.3.1 North America Amyloidosis Therapeutics Sales by Country (2017-2028)
        6.3.2 North America Amyloidosis Therapeutics Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Amyloidosis Therapeutics Market Size by Type
        7.1.1 Europe Amyloidosis Therapeutics Sales by Type (2017-2028)
        7.1.2 Europe Amyloidosis Therapeutics Revenue by Type (2017-2028)
    7.2 Europe Amyloidosis Therapeutics Market Size by Application
        7.2.1 Europe Amyloidosis Therapeutics Sales by Application (2017-2028)
        7.2.2 Europe Amyloidosis Therapeutics Revenue by Application (2017-2028)
    7.3 Europe Amyloidosis Therapeutics Market Size by Country
        7.3.1 Europe Amyloidosis Therapeutics Sales by Country (2017-2028)
        7.3.2 Europe Amyloidosis Therapeutics Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Amyloidosis Therapeutics Market Size by Type
        8.1.1 Asia Pacific Amyloidosis Therapeutics Sales by Type (2017-2028)
        8.1.2 Asia Pacific Amyloidosis Therapeutics Revenue by Type (2017-2028)
    8.2 Asia Pacific Amyloidosis Therapeutics Market Size by Application
        8.2.1 Asia Pacific Amyloidosis Therapeutics Sales by Application (2017-2028)
        8.2.2 Asia Pacific Amyloidosis Therapeutics Revenue by Application (2017-2028)
    8.3 Asia Pacific Amyloidosis Therapeutics Market Size by Region
        8.3.1 Asia Pacific Amyloidosis Therapeutics Sales by Region (2017-2028)
        8.3.2 Asia Pacific Amyloidosis Therapeutics Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Amyloidosis Therapeutics Market Size by Type
        9.1.1 Latin America Amyloidosis Therapeutics Sales by Type (2017-2028)
        9.1.2 Latin America Amyloidosis Therapeutics Revenue by Type (2017-2028)
    9.2 Latin America Amyloidosis Therapeutics Market Size by Application
        9.2.1 Latin America Amyloidosis Therapeutics Sales by Application (2017-2028)
        9.2.2 Latin America Amyloidosis Therapeutics Revenue by Application (2017-2028)
    9.3 Latin America Amyloidosis Therapeutics Market Size by Country
        9.3.1 Latin America Amyloidosis Therapeutics Sales by Country (2017-2028)
        9.3.2 Latin America Amyloidosis Therapeutics Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Amyloidosis Therapeutics Market Size by Type
        10.1.1 Middle East and Africa Amyloidosis Therapeutics Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Amyloidosis Therapeutics Revenue by Type (2017-2028)
    10.2 Middle East and Africa Amyloidosis Therapeutics Market Size by Application
        10.2.1 Middle East and Africa Amyloidosis Therapeutics Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Amyloidosis Therapeutics Revenue by Application (2017-2028)
    10.3 Middle East and Africa Amyloidosis Therapeutics Market Size by Country
        10.3.1 Middle East and Africa Amyloidosis Therapeutics Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Amyloidosis Therapeutics Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 Pfizer Inc.
        11.1.1 Pfizer Inc. Corporation Information
        11.1.2 Pfizer Inc. Overview
        11.1.3 Pfizer Inc. Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 Pfizer Inc. Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 Pfizer Inc. Recent Developments
    11.2 ProteoTech, Inc.
        11.2.1 ProteoTech, Inc. Corporation Information
        11.2.2 ProteoTech, Inc. Overview
        11.2.3 ProteoTech, Inc. Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 ProteoTech, Inc. Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 ProteoTech, Inc. Recent Developments
    11.3 Alnylam Pharmaceuticals, Inc.
        11.3.1 Alnylam Pharmaceuticals, Inc. Corporation Information
        11.3.2 Alnylam Pharmaceuticals, Inc. Overview
        11.3.3 Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 Alnylam Pharmaceuticals, Inc. Recent Developments
    11.4 Arcturus Therapeutics, Inc
        11.4.1 Arcturus Therapeutics, Inc Corporation Information
        11.4.2 Arcturus Therapeutics, Inc Overview
        11.4.3 Arcturus Therapeutics, Inc Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 Arcturus Therapeutics, Inc Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 Arcturus Therapeutics, Inc Recent Developments
    11.5 Bellus Health Inc.
        11.5.1 Bellus Health Inc. Corporation Information
        11.5.2 Bellus Health Inc. Overview
        11.5.3 Bellus Health Inc. Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Bellus Health Inc. Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Bellus Health Inc. Recent Developments
    11.6 Bsim2
        11.6.1 Bsim2 Corporation Information
        11.6.2 Bsim2 Overview
        11.6.3 Bsim2 Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
        11.6.4 Bsim2 Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
        11.6.5 Bsim2 Recent Developments
    11.7 Celgene Corporation
        11.7.1 Celgene Corporation Corporation Information
        11.7.2 Celgene Corporation Overview
        11.7.3 Celgene Corporation Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
        11.7.4 Celgene Corporation Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
        11.7.5 Celgene Corporation Recent Developments
    11.8 Millennium Pharmaceuticals, Inc.
        11.8.1 Millennium Pharmaceuticals, Inc. Corporation Information
        11.8.2 Millennium Pharmaceuticals, Inc. Overview
        11.8.3 Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
        11.8.4 Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
        11.8.5 Millennium Pharmaceuticals, Inc. Recent Developments
    11.9 Onyx Pharmaceuticals, Inc.
        11.9.1 Onyx Pharmaceuticals, Inc. Corporation Information
        11.9.2 Onyx Pharmaceuticals, Inc. Overview
        11.9.3 Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
        11.9.4 Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
        11.9.5 Onyx Pharmaceuticals, Inc. Recent Developments
    11.10 GlaxoSmithKline Plc
        11.10.1 GlaxoSmithKline Plc Corporation Information
        11.10.2 GlaxoSmithKline Plc Overview
        11.10.3 GlaxoSmithKline Plc Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
        11.10.4 GlaxoSmithKline Plc Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
        11.10.5 GlaxoSmithKline Plc Recent Developments
    11.11 Isis Pharmaceuticals, Inc.
        11.11.1 Isis Pharmaceuticals, Inc. Corporation Information
        11.11.2 Isis Pharmaceuticals, Inc. Overview
        11.11.3 Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
        11.11.4 Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
        11.11.5 Isis Pharmaceuticals, Inc. Recent Developments
    11.12 Prothena Corporation Plc
        11.12.1 Prothena Corporation Plc Corporation Information
        11.12.2 Prothena Corporation Plc Overview
        11.12.3 Prothena Corporation Plc Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
        11.12.4 Prothena Corporation Plc Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
        11.12.5 Prothena Corporation Plc Recent Developments
    11.13 SOM Innovation Biotech SL
        11.13.1 SOM Innovation Biotech SL Corporation Information
        11.13.2 SOM Innovation Biotech SL Overview
        11.13.3 SOM Innovation Biotech SL Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
        11.13.4 SOM Innovation Biotech SL Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
        11.13.5 SOM Innovation Biotech SL Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Amyloidosis Therapeutics Industry Chain Analysis
    12.2 Amyloidosis Therapeutics Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Amyloidosis Therapeutics Production Mode & Process
    12.4 Amyloidosis Therapeutics Sales and Marketing
        12.4.1 Amyloidosis Therapeutics Sales Channels
        12.4.2 Amyloidosis Therapeutics Distributors
    12.5 Amyloidosis Therapeutics Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Amyloidosis Therapeutics Industry Trends
    13.2 Amyloidosis Therapeutics Market Drivers
    13.3 Amyloidosis Therapeutics Market Challenges
    13.4 Amyloidosis Therapeutics Market Restraints
14 Key Findings in The Global Amyloidosis Therapeutics Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer
List of Tables
    Table 1. Global Amyloidosis Therapeutics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of AG-10
    Table 3. Major Manufacturers of ALN-ANG
    Table 4. Major Manufacturers of ALN-TTRsc02
    Table 5. Major Manufacturers of CAEL-101
    Table 6. Major Manufacturers of Canakinumab
    Table 7. Major Manufacturers of Others
    Table 8. Global Amyloidosis Therapeutics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 9. Global Amyloidosis Therapeutics Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 10. Global Amyloidosis Therapeutics Sales by Region (2017-2022) & (K Pcs)
    Table 11. Global Amyloidosis Therapeutics Sales Market Share by Region (2017-2022)
    Table 12. Global Amyloidosis Therapeutics Sales by Region (2023-2028) & (K Pcs)
    Table 13. Global Amyloidosis Therapeutics Sales Market Share by Region (2023-2028)
    Table 14. Global Amyloidosis Therapeutics Revenue by Region (2017-2022) & (US$ Million)
    Table 15. Global Amyloidosis Therapeutics Revenue Market Share by Region (2017-2022)
    Table 16. Global Amyloidosis Therapeutics Revenue by Region (2023-2028) & (US$ Million)
    Table 17. Global Amyloidosis Therapeutics Revenue Market Share by Region (2023-2028)
    Table 18. Global Amyloidosis Therapeutics Sales by Manufacturers (2017-2022) & (K Pcs)
    Table 19. Global Amyloidosis Therapeutics Sales Share by Manufacturers (2017-2022)
    Table 20. Global Amyloidosis Therapeutics Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 21. Global Amyloidosis Therapeutics Revenue Share by Manufacturers (2017-2022)
    Table 22. Amyloidosis Therapeutics Price by Manufacturers (2017-2022) &(USD/Pcs)
    Table 23. Global Amyloidosis Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 24. Global Amyloidosis Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Amyloidosis Therapeutics as of 2021)
    Table 25. Amyloidosis Therapeutics Manufacturing Base Distribution and Headquarters
    Table 26. Manufacturers Amyloidosis Therapeutics Product Offered
    Table 27. Date of Manufacturers Enter into Amyloidosis Therapeutics Market
    Table 28. Mergers & Acquisitions, Expansion Plans
    Table 29. Global Amyloidosis Therapeutics Sales by Type (2017-2022) & (K Pcs)
    Table 30. Global Amyloidosis Therapeutics Sales by Type (2023-2028) & (K Pcs)
    Table 31. Global Amyloidosis Therapeutics Sales Share by Type (2017-2022)
    Table 32. Global Amyloidosis Therapeutics Sales Share by Type (2023-2028)
    Table 33. Global Amyloidosis Therapeutics Revenue by Type (2017-2022) & (US$ Million)
    Table 34. Global Amyloidosis Therapeutics Revenue by Type (2023-2028) & (US$ Million)
    Table 35. Global Amyloidosis Therapeutics Revenue Share by Type (2017-2022)
    Table 36. Global Amyloidosis Therapeutics Revenue Share by Type (2023-2028)
    Table 37. Amyloidosis Therapeutics Price by Type (2017-2022) & (USD/Pcs)
    Table 38. Global Amyloidosis Therapeutics Price Forecast by Type (2023-2028) & (USD/Pcs)
    Table 39. Global Amyloidosis Therapeutics Sales by Application (2017-2022) & (K Pcs)
    Table 40. Global Amyloidosis Therapeutics Sales by Application (2023-2028) & (K Pcs)
    Table 41. Global Amyloidosis Therapeutics Sales Share by Application (2017-2022)
    Table 42. Global Amyloidosis Therapeutics Sales Share by Application (2023-2028)
    Table 43. Global Amyloidosis Therapeutics Revenue by Application (2017-2022) & (US$ Million)
    Table 44. Global Amyloidosis Therapeutics Revenue by Application (2023-2028) & (US$ Million)
    Table 45. Global Amyloidosis Therapeutics Revenue Share by Application (2017-2022)
    Table 46. Global Amyloidosis Therapeutics Revenue Share by Application (2023-2028)
    Table 47. Amyloidosis Therapeutics Price by Application (2017-2022) & (USD/Pcs)
    Table 48. Global Amyloidosis Therapeutics Price Forecast by Application (2023-2028) & (USD/Pcs)
    Table 49. North America Amyloidosis Therapeutics Sales by Type (2017-2022) & (K Pcs)
    Table 50. North America Amyloidosis Therapeutics Sales by Type (2023-2028) & (K Pcs)
    Table 51. North America Amyloidosis Therapeutics Revenue by Type (2017-2022) & (US$ Million)
    Table 52. North America Amyloidosis Therapeutics Revenue by Type (2023-2028) & (US$ Million)
    Table 53. North America Amyloidosis Therapeutics Sales by Application (2017-2022) & (K Pcs)
    Table 54. North America Amyloidosis Therapeutics Sales by Application (2023-2028) & (K Pcs)
    Table 55. North America Amyloidosis Therapeutics Revenue by Application (2017-2022) & (US$ Million)
    Table 56. North America Amyloidosis Therapeutics Revenue by Application (2023-2028) & (US$ Million)
    Table 57. North America Amyloidosis Therapeutics Sales by Country (2017-2022) & (K Pcs)
    Table 58. North America Amyloidosis Therapeutics Sales by Country (2023-2028) & (K Pcs)
    Table 59. North America Amyloidosis Therapeutics Revenue by Country (2017-2022) & (US$ Million)
    Table 60. North America Amyloidosis Therapeutics Revenue by Country (2023-2028) & (US$ Million)
    Table 61. Europe Amyloidosis Therapeutics Sales by Type (2017-2022) & (K Pcs)
    Table 62. Europe Amyloidosis Therapeutics Sales by Type (2023-2028) & (K Pcs)
    Table 63. Europe Amyloidosis Therapeutics Revenue by Type (2017-2022) & (US$ Million)
    Table 64. Europe Amyloidosis Therapeutics Revenue by Type (2023-2028) & (US$ Million)
    Table 65. Europe Amyloidosis Therapeutics Sales by Application (2017-2022) & (K Pcs)
    Table 66. Europe Amyloidosis Therapeutics Sales by Application (2023-2028) & (K Pcs)
    Table 67. Europe Amyloidosis Therapeutics Revenue by Application (2017-2022) & (US$ Million)
    Table 68. Europe Amyloidosis Therapeutics Revenue by Application (2023-2028) & (US$ Million)
    Table 69. Europe Amyloidosis Therapeutics Sales by Country (2017-2022) & (K Pcs)
    Table 70. Europe Amyloidosis Therapeutics Sales by Country (2023-2028) & (K Pcs)
    Table 71. Europe Amyloidosis Therapeutics Revenue by Country (2017-2022) & (US$ Million)
    Table 72. Europe Amyloidosis Therapeutics Revenue by Country (2023-2028) & (US$ Million)
    Table 73. Asia Pacific Amyloidosis Therapeutics Sales by Type (2017-2022) & (K Pcs)
    Table 74. Asia Pacific Amyloidosis Therapeutics Sales by Type (2023-2028) & (K Pcs)
    Table 75. Asia Pacific Amyloidosis Therapeutics Revenue by Type (2017-2022) & (US$ Million)
    Table 76. Asia Pacific Amyloidosis Therapeutics Revenue by Type (2023-2028) & (US$ Million)
    Table 77. Asia Pacific Amyloidosis Therapeutics Sales by Application (2017-2022) & (K Pcs)
    Table 78. Asia Pacific Amyloidosis Therapeutics Sales by Application (2023-2028) & (K Pcs)
    Table 79. Asia Pacific Amyloidosis Therapeutics Revenue by Application (2017-2022) & (US$ Million)
    Table 80. Asia Pacific Amyloidosis Therapeutics Revenue by Application (2023-2028) & (US$ Million)
    Table 81. Asia Pacific Amyloidosis Therapeutics Sales by Region (2017-2022) & (K Pcs)
    Table 82. Asia Pacific Amyloidosis Therapeutics Sales by Region (2023-2028) & (K Pcs)
    Table 83. Asia Pacific Amyloidosis Therapeutics Revenue by Region (2017-2022) & (US$ Million)
    Table 84. Asia Pacific Amyloidosis Therapeutics Revenue by Region (2023-2028) & (US$ Million)
    Table 85. Latin America Amyloidosis Therapeutics Sales by Type (2017-2022) & (K Pcs)
    Table 86. Latin America Amyloidosis Therapeutics Sales by Type (2023-2028) & (K Pcs)
    Table 87. Latin America Amyloidosis Therapeutics Revenue by Type (2017-2022) & (US$ Million)
    Table 88. Latin America Amyloidosis Therapeutics Revenue by Type (2023-2028) & (US$ Million)
    Table 89. Latin America Amyloidosis Therapeutics Sales by Application (2017-2022) & (K Pcs)
    Table 90. Latin America Amyloidosis Therapeutics Sales by Application (2023-2028) & (K Pcs)
    Table 91. Latin America Amyloidosis Therapeutics Revenue by Application (2017-2022) & (US$ Million)
    Table 92. Latin America Amyloidosis Therapeutics Revenue by Application (2023-2028) & (US$ Million)
    Table 93. Latin America Amyloidosis Therapeutics Sales by Country (2017-2022) & (K Pcs)
    Table 94. Latin America Amyloidosis Therapeutics Sales by Country (2023-2028) & (K Pcs)
    Table 95. Latin America Amyloidosis Therapeutics Revenue by Country (2017-2022) & (US$ Million)
    Table 96. Latin America Amyloidosis Therapeutics Revenue by Country (2023-2028) & (US$ Million)
    Table 97. Middle East and Africa Amyloidosis Therapeutics Sales by Type (2017-2022) & (K Pcs)
    Table 98. Middle East and Africa Amyloidosis Therapeutics Sales by Type (2023-2028) & (K Pcs)
    Table 99. Middle East and Africa Amyloidosis Therapeutics Revenue by Type (2017-2022) & (US$ Million)
    Table 100. Middle East and Africa Amyloidosis Therapeutics Revenue by Type (2023-2028) & (US$ Million)
    Table 101. Middle East and Africa Amyloidosis Therapeutics Sales by Application (2017-2022) & (K Pcs)
    Table 102. Middle East and Africa Amyloidosis Therapeutics Sales by Application (2023-2028) & (K Pcs)
    Table 103. Middle East and Africa Amyloidosis Therapeutics Revenue by Application (2017-2022) & (US$ Million)
    Table 104. Middle East and Africa Amyloidosis Therapeutics Revenue by Application (2023-2028) & (US$ Million)
    Table 105. Middle East and Africa Amyloidosis Therapeutics Sales by Country (2017-2022) & (K Pcs)
    Table 106. Middle East and Africa Amyloidosis Therapeutics Sales by Country (2023-2028) & (K Pcs)
    Table 107. Middle East and Africa Amyloidosis Therapeutics Revenue by Country (2017-2022) & (US$ Million)
    Table 108. Middle East and Africa Amyloidosis Therapeutics Revenue by Country (2023-2028) & (US$ Million)
    Table 109. Pfizer Inc. Corporation Information
    Table 110. Pfizer Inc. Description and Major Businesses
    Table 111. Pfizer Inc. Amyloidosis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 112. Pfizer Inc. Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    Table 113. Pfizer Inc. Recent Developments
    Table 114. ProteoTech, Inc. Corporation Information
    Table 115. ProteoTech, Inc. Description and Major Businesses
    Table 116. ProteoTech, Inc. Amyloidosis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 117. ProteoTech, Inc. Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    Table 118. ProteoTech, Inc. Recent Developments
    Table 119. Alnylam Pharmaceuticals, Inc. Corporation Information
    Table 120. Alnylam Pharmaceuticals, Inc. Description and Major Businesses
    Table 121. Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 122. Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    Table 123. Alnylam Pharmaceuticals, Inc. Recent Developments
    Table 124. Arcturus Therapeutics, Inc Corporation Information
    Table 125. Arcturus Therapeutics, Inc Description and Major Businesses
    Table 126. Arcturus Therapeutics, Inc Amyloidosis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 127. Arcturus Therapeutics, Inc Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    Table 128. Arcturus Therapeutics, Inc Recent Developments
    Table 129. Bellus Health Inc. Corporation Information
    Table 130. Bellus Health Inc. Description and Major Businesses
    Table 131. Bellus Health Inc. Amyloidosis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 132. Bellus Health Inc. Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    Table 133. Bellus Health Inc. Recent Developments
    Table 134. Bsim2 Corporation Information
    Table 135. Bsim2 Description and Major Businesses
    Table 136. Bsim2 Amyloidosis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 137. Bsim2 Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    Table 138. Bsim2 Recent Developments
    Table 139. Celgene Corporation Corporation Information
    Table 140. Celgene Corporation Description and Major Businesses
    Table 141. Celgene Corporation Amyloidosis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 142. Celgene Corporation Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    Table 143. Celgene Corporation Recent Developments
    Table 144. Millennium Pharmaceuticals, Inc. Corporation Information
    Table 145. Millennium Pharmaceuticals, Inc. Description and Major Businesses
    Table 146. Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 147. Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    Table 148. Millennium Pharmaceuticals, Inc. Recent Developments
    Table 149. Onyx Pharmaceuticals, Inc. Corporation Information
    Table 150. Onyx Pharmaceuticals, Inc. Description and Major Businesses
    Table 151. Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 152. Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    Table 153. Onyx Pharmaceuticals, Inc. Recent Developments
    Table 154. GlaxoSmithKline Plc Corporation Information
    Table 155. GlaxoSmithKline Plc Description and Major Businesses
    Table 156. GlaxoSmithKline Plc Amyloidosis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 157. GlaxoSmithKline Plc Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    Table 158. GlaxoSmithKline Plc Recent Developments
    Table 159. Isis Pharmaceuticals, Inc. Corporation Information
    Table 160. Isis Pharmaceuticals, Inc. Description and Major Businesses
    Table 161. Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 162. Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    Table 163. Isis Pharmaceuticals, Inc. Recent Developments
    Table 164. Prothena Corporation Plc Corporation Information
    Table 165. Prothena Corporation Plc Description and Major Businesses
    Table 166. Prothena Corporation Plc Amyloidosis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 167. Prothena Corporation Plc Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    Table 168. Prothena Corporation Plc Recent Developments
    Table 169. SOM Innovation Biotech SL Corporation Information
    Table 170. SOM Innovation Biotech SL Description and Major Businesses
    Table 171. SOM Innovation Biotech SL Amyloidosis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 172. SOM Innovation Biotech SL Amyloidosis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    Table 173. SOM Innovation Biotech SL Recent Developments
    Table 174. Key Raw Materials Lists
    Table 175. Raw Materials Key Suppliers Lists
    Table 176. Amyloidosis Therapeutics Distributors List
    Table 177. Amyloidosis Therapeutics Customers List
    Table 178. Amyloidosis Therapeutics Market Trends
    Table 179. Amyloidosis Therapeutics Market Drivers
    Table 180. Amyloidosis Therapeutics Market Challenges
    Table 181. Amyloidosis Therapeutics Market Restraints
    Table 182. Research Programs/Design for This Report
    Table 183. Key Data Information from Secondary Sources
    Table 184. Key Data Information from Primary Sources
List of Figures
    Figure 1. Amyloidosis Therapeutics Product Picture
    Figure 3. Global Amyloidosis Therapeutics Market Share by Type in 2021 & 2028
    Figure 3. AG-10 Product Picture
    Figure 4. ALN-ANG Product Picture
    Figure 5. ALN-TTRsc02 Product Picture
    Figure 6. CAEL-101 Product Picture
    Figure 7. Canakinumab Product Picture
    Figure 8. Others Product Picture
    Figure 9. Global Amyloidosis Therapeutics Market Share by Application in 2021 & 2028
    Figure 10. AL Amyloidosis
    Figure 11. AA Amyloidoses
    Figure 12. ATTR Amyloidoses
    Figure 13. Others
    Figure 14. Amyloidosis Therapeutics Report Years Considered
    Figure 15. Global Amyloidosis Therapeutics Sales 2017-2028 (K Pcs)
    Figure 16. Global Amyloidosis Therapeutics Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 17. Global Amyloidosis Therapeutics Revenue 2017-2028 (US$ Million)
    Figure 18. Global Amyloidosis Therapeutics Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 19. Global Amyloidosis Therapeutics Sales Market Share by Region (2017-2022)
    Figure 20. Global Amyloidosis Therapeutics Sales Market Share by Region (2023-2028)
    Figure 21. North America Amyloidosis Therapeutics Sales YoY (2017-2028) & (K Pcs)
    Figure 22. North America Amyloidosis Therapeutics Revenue YoY (2017-2028) & (US$ Million)
    Figure 23. Europe Amyloidosis Therapeutics Sales YoY (2017-2028) & (K Pcs)
    Figure 24. Europe Amyloidosis Therapeutics Revenue YoY (2017-2028) & (US$ Million)
    Figure 25. Asia-Pacific Amyloidosis Therapeutics Sales YoY (2017-2028) & (K Pcs)
    Figure 26. Asia-Pacific Amyloidosis Therapeutics Revenue YoY (2017-2028) & (US$ Million)
    Figure 27. Latin America Amyloidosis Therapeutics Sales YoY (2017-2028) & (K Pcs)
    Figure 28. Latin America Amyloidosis Therapeutics Revenue YoY (2017-2028) & (US$ Million)
    Figure 29. Middle East & Africa Amyloidosis Therapeutics Sales YoY (2017-2028) & (K Pcs)
    Figure 30. Middle East & Africa Amyloidosis Therapeutics Revenue YoY (2017-2028) & (US$ Million)
    Figure 31. The Amyloidosis Therapeutics Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 32. The Top 5 and 10 Largest Manufacturers of Amyloidosis Therapeutics in the World: Market Share by Amyloidosis Therapeutics Revenue in 2021
    Figure 33. Global Amyloidosis Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 34. Global Amyloidosis Therapeutics Sales Market Share by Type (2017-2028)
    Figure 35. Global Amyloidosis Therapeutics Revenue Market Share by Type (2017-2028)
    Figure 36. Global Amyloidosis Therapeutics Sales Market Share by Application (2017-2028)
    Figure 37. Global Amyloidosis Therapeutics Revenue Market Share by Application (2017-2028)
    Figure 38. North America Amyloidosis Therapeutics Sales Market Share by Type (2017-2028)
    Figure 39. North America Amyloidosis Therapeutics Revenue Market Share by Type (2017-2028)
    Figure 40. North America Amyloidosis Therapeutics Sales Market Share by Application (2017-2028)
    Figure 41. North America Amyloidosis Therapeutics Revenue Market Share by Application (2017-2028)
    Figure 42. North America Amyloidosis Therapeutics Sales Share by Country (2017-2028)
    Figure 43. North America Amyloidosis Therapeutics Revenue Share by Country (2017-2028)
    Figure 44. U.S. Amyloidosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 45. Canada Amyloidosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 46. Europe Amyloidosis Therapeutics Sales Market Share by Type (2017-2028)
    Figure 47. Europe Amyloidosis Therapeutics Revenue Market Share by Type (2017-2028)
    Figure 48. Europe Amyloidosis Therapeutics Sales Market Share by Application (2017-2028)
    Figure 49. Europe Amyloidosis Therapeutics Revenue Market Share by Application (2017-2028)
    Figure 50. Europe Amyloidosis Therapeutics Sales Share by Country (2017-2028)
    Figure 51. Europe Amyloidosis Therapeutics Revenue Share by Country (2017-2028)
    Figure 52. Germany Amyloidosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 53. France Amyloidosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 54. U.K. Amyloidosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 55. Italy Amyloidosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 56. Russia Amyloidosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 57. Asia Pacific Amyloidosis Therapeutics Sales Market Share by Type (2017-2028)
    Figure 58. Asia Pacific Amyloidosis Therapeutics Revenue Market Share by Type (2017-2028)
    Figure 59. Asia Pacific Amyloidosis Therapeutics Sales Market Share by Application (2017-2028)
    Figure 60. Asia Pacific Amyloidosis Therapeutics Revenue Market Share by Application (2017-2028)
    Figure 61. Asia Pacific Amyloidosis Therapeutics Sales Share by Region (2017-2028)
    Figure 62. Asia Pacific Amyloidosis Therapeutics Revenue Share by Region (2017-2028)
    Figure 63. China Amyloidosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 64. Japan Amyloidosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 65. South Korea Amyloidosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 66. India Amyloidosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 67. Australia Amyloidosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 68. Taiwan Amyloidosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 69. Indonesia Amyloidosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 70. Thailand Amyloidosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 71. Malaysia Amyloidosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 72. Philippines Amyloidosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 73. Latin America Amyloidosis Therapeutics Sales Market Share by Type (2017-2028)
    Figure 74. Latin America Amyloidosis Therapeutics Revenue Market Share by Type (2017-2028)
    Figure 75. Latin America Amyloidosis Therapeutics Sales Market Share by Application (2017-2028)
    Figure 76. Latin America Amyloidosis Therapeutics Revenue Market Share by Application (2017-2028)
    Figure 77. Latin America Amyloidosis Therapeutics Sales Share by Country (2017-2028)
    Figure 78. Latin America Amyloidosis Therapeutics Revenue Share by Country (2017-2028)
    Figure 79. Mexico Amyloidosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 80. Brazil Amyloidosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 81. Argentina Amyloidosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 82. Middle East and Africa Amyloidosis Therapeutics Sales Market Share by Type (2017-2028)
    Figure 83. Middle East and Africa Amyloidosis Therapeutics Revenue Market Share by Type (2017-2028)
    Figure 84. Middle East and Africa Amyloidosis Therapeutics Sales Market Share by Application (2017-2028)
    Figure 85. Middle East and Africa Amyloidosis Therapeutics Revenue Market Share by Application (2017-2028)
    Figure 86. Middle East and Africa Amyloidosis Therapeutics Sales Share by Country (2017-2028)
    Figure 87. Middle East and Africa Amyloidosis Therapeutics Revenue Share by Country (2017-2028)
    Figure 88. Turkey Amyloidosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 89. Saudi Arabia Amyloidosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 90. UAE Amyloidosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 91. Amyloidosis Therapeutics Value Chain
    Figure 92. Amyloidosis Therapeutics Production Process
    Figure 93. Channels of Distribution
    Figure 94. Distributors Profiles
    Figure 95. Bottom-up and Top-down Approaches for This Report
    Figure 96. Data Triangulation
    Figure 97. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Pfizer Inc.
ProteoTech, Inc.
Alnylam Pharmaceuticals, Inc.
Arcturus Therapeutics, Inc
Bellus Health Inc.
Bsim2
Celgene Corporation
Millennium Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc.
GlaxoSmithKline Plc
Isis Pharmaceuticals, Inc.
Prothena Corporation Plc
SOM Innovation Biotech SL
Frequently Asked Questions
Amyloidosis Therapeutics report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Amyloidosis Therapeutics report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Amyloidosis Therapeutics report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Industrial Staircase

Industrial Staircase market is segmented by Type and by Application. Players, stakeholders, and o ... Read More

Dock Shelters

Dock Shelters market is segmented by Type and by Application. Players, stakeholders, and other pa ... Read More